Ofatumumab is administered as an intravenous (IV) infusion. It is supplied as a clear, colorless liquid concentrate in single-use vials. The medication is diluted in saline and given through a vein, typically in a hospital or clinic setting where you can be closely monitored.

The dosing schedule depends on the specific treatment plan for chronic lymphocytic leukemia (CLL):

For previously untreated CLL (with chlorambucil): 300 mg on Day 1, 1,000 mg on Day 8, then 1,000 mg on Day 1 of each 28-day cycle for at least 3 cycles (up to 12 cycles).
For relapsed CLL (with fludarabine and cyclophosphamide): 300 mg on Day 1, 1,000 mg on Day 8, then 1,000 mg on Day 1 of each 28-day cycle for up to 6 cycles.
For extended treatment: 300 mg on Day 1, 1,000 mg on Day 8, then 1,000 mg every 8 weeks for up to 2 years.
For refractory CLL: 300 mg on Day 1, 2,000 mg weekly for 7 doses, then 2,000 mg every 4 weeks for 4 doses.

Premedication with acetaminophen, antihistamines, and corticosteroids is recommended before each infusion to help prevent reactions.

ofatumumab

Common brand names

Approved use in